title: Prostatic stromal sarcoma with neuroectodermal differentiation.
abstract: Prostatic stromal sarcoma is a fairly rare tumor that constitutes approximately 0.1-0.2% of all prostatic cancers. Detailed characteristics of the tumor are still unclear due to its rarity.We describe a case of prostatic stromal sarcoma in a 63 year-old man who suffered from urinary obstructive symptoms. Palliative transuterine resection was performed and the preliminary histopathological diagnosis was neuroendocrine carcinoma. After chemotherapy, total pelvic exenteration was performed. Histopathologically, the tumor was composed of monotonously proliferating small to medium-sized round cells, which existed in compact islands with loose or dense fibrovascular networks. Immunohistochemically, the tumor cells were widely positive for vimentin, CD56, CD99 and focally positive for synaptophysin, CD10, progesterone receptor, desmin and CD34, but negative for EMA, cytokeratin, estrogen receptor, S-100 and myoglobin. Most of the previously reported tumors exhibited positive stainability for CD10 and progesterone receptor. In addition to these markers, expressions of CD56, CD99 and synaptophysin were characteristically detected in our case. To the best of our knowledge, we present the first case of prostatic stromal sarcoma with characteristic immunohistochemical staining properties. Although the biological characteristics of this rare tumor have not yet been elucidated, these findings suggest prostatic stromal sarcoma can potentially show neuroectodermal differentiation.
  The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7291874028051262.
authors.affiliation: Department of Pathology, Medical center hospital, Kitasato Institute, Kitasato University, Saitama, Japan. powder1104@hotmail.com
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Teppei
authors.initials: T
authors.lastname: Ohyama
authors.forename: Toshiki
authors.initials: T
authors.lastname: Tsuboi
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Taoka
authors.forename: Dai
authors.initials: D
authors.lastname: Kohguchi
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Iguchi
authors.forename: Teruaki
authors.initials: T
authors.lastname: Ao
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D002454:Cell Differentiation; D049109:Cell Proliferation; D006801:Humans; D007150:Immunohistochemistry; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018193:Neoplasms, Complex and Mixed / Q000737:chemistry / Q000473:pathology* / Q000628:therapy; D017599:Neuroectodermal Tumors / Q000737:chemistry / Q000473:pathology* / Q000628:therapy; D011471:Prostatic Neoplasms / Q000737:chemistry / Q000473:pathology* / Q000628:therapy; D012509:Sarcoma / Q000737:chemistry / Q000473:pathology* / Q000601:surgery; D017154:Stromal Cells / Q000737:chemistry / Q000473:pathology*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor